Hansoh Pharma's Class 1 New Drug HS-20152 Granted IND Approval for Paroxysmal Nocturnal Hemoglobinuria

On March 23, Hansoh Pharma (03692) announced that the company's self-developed Class 1 new drug, HS-20152 Injection, received clinical trial approval from the China National Medical Products Administration (NMPA) to conduct clinical trials for paroxysmal nocturnal hemoglobinuria.